These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 21878041)

  • 1. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R; Ceconi C
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
    Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
    Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC; Reil GH; Böhm M
    Trends Cardiovasc Med; 2009 Jul; 19(5):152-7. PubMed ID: 20005474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N; Bhargava B
    Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS; Le Heuzey JY
    Am J Ther; 2008; 15(5):461-73. PubMed ID: 18806523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO; Celik S; Ehlermann P; Frankenstein L; Zehelein J; Koch A; Katus HA; Dengler TJ
    Transplantation; 2007 Oct; 84(8):988-96. PubMed ID: 17989604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E; Bonadei I; D'Aloia A; Del Magro F; Piovanelli B; Bontempi L; Curnis A; Dei Cas L
    Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I(f) inhibition in cardiovascular diseases.
    Thollon C; Vilaine JP
    Adv Pharmacol; 2010; 59():53-92. PubMed ID: 20933199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-ischaemic effect of ivabradine.
    Ferrari R; Cargnoni A; Ceconi C
    Pharmacol Res; 2006 May; 53(5):435-9. PubMed ID: 16644235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.
    Monnet X; Ghaleh B; Colin P; de Curzon OP; Giudicelli JF; Berdeaux A
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1133-9. PubMed ID: 11714904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Chronic Heart Rate Reduction by I(f) Current Inhibitor Ivabradine on Left Ventricular Remodeling and Systolic Performance in Middle-Aged Rats With Postmyocardial Infarction Heart Failure.
    Dedkov EI; Bogatyryov Y; McCooey DS; Christensen LP; Weiss RM; Tomanek RJ
    J Cardiovasc Pharmacol Ther; 2015 May; 20(3):299-312. PubMed ID: 25287895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective effects of the Ιf current inhibition by ivabradine during cardiac dysfunction.
    Su JB
    Curr Pharm Biotechnol; 2014; 14(14):1213-9. PubMed ID: 24831809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs.
    Colin P; Ghaleh B; Monnet X; Hittinger L; Berdeaux A
    J Pharmacol Exp Ther; 2004 Jan; 308(1):236-40. PubMed ID: 14569053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM; Vitale C; Volterrani M
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.